(Q44990894)

8 December 2017

title

Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. (English)

1 reference

8 December 2017

0 references

1 reference

E Richtig

1

1 reference

8 December 2017

R Hofmann-Wellenhof

2

1 reference

8 December 2017

H Pehamberger

3

1 reference

8 December 2017

Ch Forstinger

4

1 reference

8 December 2017

K Wolff

5

1 reference

8 December 2017

P Mischer

6

1 reference

8 December 2017

J Raml

7

1 reference

8 December 2017

P Fritsch

8

1 reference

8 December 2017

B Zelger

9

1 reference

8 December 2017

G Ratzinger

10

1 reference

8 December 2017

J Koller

11

1 reference

8 December 2017

A Lang

12

1 reference

8 December 2017

K Konrad

13

1 reference

8 December 2017

E Kindermann-Glebowski

14

1 reference

8 December 2017

A Seeber

15

1 reference

8 December 2017

A Steiner

16

1 reference

8 December 2017

R Fialla

17

1 reference

8 December 2017

W Pachinger

18

1 reference

8 December 2017

C Kos

19

1 reference

8 December 2017

G Klein

20

1 reference

8 December 2017

H Kehrer

21

1 reference

8 December 2017

H Kerl

22

1 reference

8 December 2017

H Ulmer

23

1 reference

8 December 2017

J Smolle

24

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

British Journal of Dermatology

8 December 2017

published in

1 reference

8 December 2017

volume

151

1 reference

8 December 2017

issue

1

1 reference

8 December 2017

page(s)

91-98

1 reference

A new American Joint Committee on Cancer staging system for cutaneous melanoma

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Experiences with therapy of stage IV metastatic malignant melanoma with "Legha Protocol" polychemoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Interferon-alpha therapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06019.X

10.1111/J.1365-2133.2004.06019.X

21 January 2018

Identifiers

DOI

1 reference

8 December 2017

1 reference